

(Office translation)

**PROTOKOLL FRA
ORDINÆR GENERALFORSAMLING**

**MINUTES OF
ANNUAL GENERAL MEETING**

I

OF

EXACT THERAPEUTICS AS

EXACT THERAPEUTICS AS

ORG. NR. 998 317 487

REG. NO. 998 317 487

Den 8. juni 2022 kl. 10.30 ble det avholdt ordinær generalforsamling i EXACT Therapeutics AS ("**Selskapet**").

The Annual General Meeting of EXACT Therapeutics AS (the "**Company**") was held on 8 June 2022 at 10:30 hours (CEST).

Generalforsamlingen ble avholdt digitalt.

The General Meeting was held electronically.

I henhold til fortegnelsen inntatt i Vedlegg 1 var 7.798.139 av totalt 29.992.167 utstedte aksjer og stemmer, som tilsvarer 26.00% av det totale antall stemmeberettigede aksjer i Selskapet, representert på generalforsamlingen.

According to the record included as Appendix 1, 7,798,139 of a total of 29,992,167 issued shares and votes, corresponding to 26.00 % of the total number of voting shares in the Company, were represented at the General Meeting.

Følgende saker ble behandlet:

The following matters were considered:

**1 ÅPNING AV
GENERALFORSAMLINGEN,
GODKJENNELSE AV INNKALLING OG
DAGSORDEN**

**1 OPENING OF THE GENERAL
MEETING, APPROVAL OF THE
SUMMONS AND AGENDA**

Styrelederen reiste spørsmål om det var noen bemerkninger til innkallingen eller dagsordenen. Da det ikke var noen innvendinger, ble innkallingen og dagsordenen ansett som godkjent. Styreleder erklærte generalforsamlingen for lovlig satt.

The Chair asked whether there were any objections to the notice or the agenda. No such objections were raised. The notice and the agenda were thus considered approved. The Chair declared the General Meeting as lawfully convened.

**2 VALG AV MØTELEDER OG ÉN PERSON
TIL Å MEDUNDERTEGNE
PROTOKOLLEN**

**2 ELECTION OF CHAIR AND PERSON
TO CO-SIGN THE MINUTES**

Masha Strømme ble valgt til møteleder. Svein Kvåle ble valgt til å undertegne protokollen sammen med møtelederen.

Masha Strømme was elected to chair the meeting. Svein Kvåle was elected to sign the minutes together with the Chair of the meeting.

Beslutningen ble truffet med nødvendig flertall, jf. avstemmingsresultat inntatt som Vedlegg 2 til protokollen.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

3 GODKJENNING AV ÅRSREGNSKAP OG STYRETS ÅRSBERETNING

I samsvar med styrets forslag ble følgende vedtatt:

Årsregnskapet, herunder konsernregnskap og årsberetning for regnskapsåret 2021, godkjennes. Det utdeles ikke utbytte for regnskapsåret 2021.

Beslutningen ble truffet med nødvendig flertall, jf. avstemmingsresultat inntatt som Vedlegg 2 til protokollen.

4 GODKJENNELSE AV HONORAR TIL REVISOR

I samsvar med styrets forslag ble følgende vedtatt:

"Generalforsamlingen godkjenner honoraret til revisor for regnskapsåret 2021 på NOK 270.000."

Beslutningen ble truffet med nødvendig flertall, jf. avstemmingsresultat inntatt som Vedlegg 2 til protokollen.

5 VALG AV STYREMEDLEMMER

Masha Strømme, Sir William Castell, Anders Wold, Ann-Tove Kongsnes og Jean-Michel Cosséry er alle på valg, mens Aitana Peire fratrer sitt styreverv.

I samsvar med nominasjonskomiteens forslag besluttet generalforsamlingen å velge følgende styresammensetning:

- Anders Wold (Styrets leder)
- Masha Strømme (nestleder)
- Sir William Castell
- Jean Michel Cosséry
- Ann-Tove Kongsnes

3 APPROVAL OF THE FINANCIAL STATEMENTS AND THE BOARD OF DIRECTORS' REPORT

In accordance with the Board of Director's proposal, the following resolution was made:

The annual accounts, including the group's annual accounts and the Board of Directors' report for the financial year 2021, are approved. No dividend is distributed for the financial year 2021.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

4 APPROVAL OF THE AUDITOR REMUNERATION

In accordance with the Board of Director's proposal, the following resolution was made:

"The General Meeting approves the remuneration to the auditor for the financial year 2021 of NOK 270,000."

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

5 ELECTION OF BOARD MEMBERS

Masha Strømme, Sir William Castell, Anders Wold, Ann-Tove Kongsnes and Jean-Michel Cosséry are all up for election, whilst Aitana Peire is stepping down from the Board.

In accordance with the Nomination Committee's proposal, the following Board composition was made:

- Anders Wold (Chair)
- Masha Strømme (Vice-Chair)
- Sir William Castell
- Jean Michel Cosséry
- Ann-Tove Kongsnes

Beslutningen ble truffet med nødvendig flertall, jf. avstemningsresultat inntatt som Vedlegg 2 til protokollen.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

6 VALG AV MEDLEMMER TIL NOMINASJONSKOMITEEN

Samtlige medlemmer av nominasjonskomiteen er på valg.

Dag Strømme fratrer som leder av nominasjonskomiteen og Leiv Askvig velges som ny leder.

I samsvar med nominasjonskomiteens forslag vedtok generalforsamlingen følgende sammensetning av nominasjonskomiteen:

- Leiv Askvig (leder)
- Dag Strømme
- Birgitte Gangmark Villmo
- Svein Kvåle

6 ELECTION OF NOMINATION COMMITTEE

All members of the Nomination Committee are up for election.

Dag Strømme will step down as Nomination Committee Chair with Leiv Askvig stepping up as Chair.

In accordance with the Nomination Committee's proposal, the following Nomination Committee composition was made:

- Leiv Askvig (Chair)
- Dag Strømme
- Birgitte Gangmark Villmo
- Svein Kvåle

Beslutningen ble truffet med nødvendig flertall, jf. avstemningsresultat inntatt som Vedlegg 2 til protokollen.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

7 HONORAR TIL STYRETS MEDLEMMER

I samsvar med nominasjonskomiteens forslag vedtok generalforsamlingen følgende honorar til styrets medlemmer for perioden fra ordinær generalforsamling i 2022 til ordinær generalforsamling i 2023:

"Generalforsamlingen godkjenner følgende honorar til styrets medlemmer:

- *Styrets leder: NOK 450.000 per år*
- *Styrets leder: 224.941 opsjoner med en innløsningskurs på NOK 19,00 tilsvarende aksjekursen som er lik den volumvektede prisen for de 10 handelsdagene før ordinær generalforsamling i 2022 (8. juni). Opsjonene opptjenes månedlig over*

7 REMUNERATION TO THE MEMBERS OF THE BOARD OF DIRECTORS

In accordance with the Nomination Committee's proposal the following resolution regarding remuneration to the members of the Board of Directors for the period from the Annual General Meeting in 2022 to 2023 was made:

"The General Meeting approves the following remuneration to the members of the Board of Directors:

- *The Chair of the Board of Directors: NOK 450,000 per year*
- *The Chair of the Board of Directors: 224,941 options with an exercise price of NOK 19.00 per share equal to the volume weighted share price for the 10 trading*

tre år og kan innløses 7 år fra datoen for ordinær generalforsamling 8. juni 2022. Opsjonene representerer 0,75 % av totalt utestående aksjer som er 29.992.167 per 30. april 2022.

- Nestleder: NOK 400.000 per år
- Øvrige styremedlemmer: NOK 180.000 per år

Honoraret utbetales som kontantbeløp hvert kvartal."

Beslutningen ble truffet med nødvendig flertall, jf. avstemmingsresultat inntatt som Vedlegg 2 til protokollen.

8 HONORAR TIL MEDLEMMENE AV NOMINASJONSKOMITEEN

I samsvar med nominasjonskomiteens forslag vedtok generalforsamlingen følgende honorar til nominasjonskomiteens medlemmer for perioden fra ordinær generalforsamling i 2022 til ordinær generalforsamling i 2023:

"Generalforsamlingen godkjenner følgende honorar til nominasjonskomiteens medlemmer:

- Komiteens leder: NOK 15.000.
- Øvrige medlemmer: NOK 10.000."

Beslutningen ble truffet med nødvendig flertall, jf. avstemmingsresultat inntatt som Vedlegg 2 til protokollen.

9 HONORAR TIL MEDLEMMENE AV KOMPENSASJONSUTVALGET

I samsvar med nominasjonskomiteens forslag vedtok generalforsamlingen følgende honorar til kompensasjonsutvalget for perioden fra ordinær generalforsamling i 2022 til ordinær generalforsamling i 2023:

days prior to the 2022 AGM (June 8). The options will vest monthly over three years and are exercisable over 7 years from the date of the AGM on June 8 2022. These options represent a total of 0.75% of the total outstanding shares of 29,992,167 as of April 30, 2022.

- Deputy chair: NOK 400,000 per year
- Other members of the Board of Directors: NOK 180,000 per year

The remuneration is paid quarterly in cash."

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

8 REMUNERATION TO THE MEMBERS OF THE NOMINATION COMMITTEE

In accordance with the Nomination Committee's proposal the following resolution regarding remuneration to the members of the Nomination Committee for the period from the Annual General Meeting in 2022 to 2023 was made:

"The General Meeting approves the following remuneration to the members of the Nomination Committee:

- The Chair of the committee: NOK 15,000
- Other members: NOK 10,000."

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

9 REMUNERATION TO THE MEMBERS OF THE REMUNERATION COMMITTEE

In accordance with the Nomination Committee's proposal the following resolution regarding remuneration to the members of the Remuneration Committee for the period from the Annual General Meeting in 2022 to 2023 was made:

"Generalforsamlingen godkjenner følgende honorar til kompensasjonsutvalget medlemmer:

- Komiteens leder: NOK 35.000
- Øvrige medlemmer: NOK 20.000

Honoraret utbetales enten som kontantbeløp hvert kvartal."

Beslutningen ble truffet med nødvendig flertall, jf. avstemmingsresultat inntatt som Vedlegg 2 til protokollen.

10 HONORAR TIL MEDLEMMENE AV REVISJONSUTVALGET

I samsvar med nominasjonskomiteens forslag vedtok generalforsamlingen følgende honorar til revisjonsutvalget for perioden fra ordinær generalforsamling i 2022 til ordinær generalforsamling i 2023:

"Generalforsamlingen godkjenner følgende honorar til revisjonsutvalgets medlemmer:

- Komiteens leder: NOK 35.000
- Øvrige medlemmer: NOK 20.000

Honoraret utbetales enten som kontantbeløp hvert kvartal."

Beslutningen ble truffet med nødvendig flertall, jf. avstemmingsresultat inntatt som Vedlegg 2 til protokollen.

11 FULLMAKTER TIL STYRET TIL Å FORHØYE AKSJEKAPITALEN VED UTSTEDELSE AV NYE AKSJER

11.1 Styrefullmakt til kapitalforhøyelser i forbindelse med oppkjøp, etc.

I samsvar med styrets forslag ble følgende vedtatt:

"The General Meeting approves the following remuneration to the members of the Remuneration Committee:

- The Chair of the committee: NOK 35,000
- Other members: NOK 20,000

The remuneration is paid quarterly in cash."

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

10 REMUNERATION TO THE MEMBERS OF THE AUDIT COMMITTEE

In accordance with the Nomination Committee's proposal the following resolution regarding remuneration to the members of the Audit Committee for the period from the Annual General Meeting in 2022 to 2023 was made:

"The General Meeting approves the following remuneration to the members of the Audit Committee:

- The Chair of the committee: NOK 35,000
- Other members: NOK 20,000

The remuneration is paid quarterly in cash."

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

11 BOARD AUTHORISATIONS TO INCREASE THE SHARE CAPITAL BY ISSUANCE OF NEW SHARES

11.1 Board authorisation for share capital increases in connection with acquisitions, etc.

In accordance with the Board of Director's proposal, the following resolution was made:

"Selskapets styre tildeles fullmakt til å gjennomføre kapitalforhøyelse, på følgende vilkår:

- a) Aksjekapitalen skal, i en eller flere omganger, kunne forhøyes med inntil NOK 17.995,30, tilsvarende 15 % av aksjekapitalen.
- b) Aksjonærenes fortrinnsrett etter aksjeloven § 10-4 kan fravikes av styret.
- c) Fullmakten gjelder fra registrering i Foretaksregisteret og frem til og med dato for ordinær generalforsamling i 2023, dog ikke senere enn 30. juni 2023.
- d) Fullmakten erstatter eksisterende fullmakt til kapitalforhøyelse gitt i ordinær generalforsamling 2021 når den blir registrert i Foretaksregisteret.
- e) Fullmakten skal omfatte kapitalforhøyelse mot innskudd i andre eiendeler enn penger, eller rett til å pådra Selskapet særlige plikter.
- f) Fullmakten omfatter kapitalforhøyelse i forbindelse med fusjon."

"The Board is authorised to increase the Company's share capital, on the following conditions:

- a) The share capital may, in one or more rounds, be increased by a total amount of up to NOK 17,995.30 corresponding to 15% of the share capital.
- b) The preferential rights pursuant to Section 10-4 of the Private Limited Liability Companies Act may be set aside by the Board of Directors.
- c) The authorisation shall be effective from the date it is registered in the Norwegian Register of Business Enterprises and shall be valid until and including the date of the Annual General Meeting in 2023, however no later than 30 June 2023.
- d) The authorisation replaces the current authorisation granted by the annual general meeting in 2021 when registered in the Norwegian Register of Business Enterprises.
- e) The authorisation covers share capital increases against or the right to assume special obligations on behalf of the Company.
- f) The authorisation covers share capital increases in connection with mergers."

Beslutningen ble truffet med nødvendig flertall, jf. avstemmingsresultat inntatt som Vedlegg 2 til protokollen.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

11.2 Styrefullmakt til kapitalforhøyelser i forbindelse med Selskapets aksjeopsjonsprogram for nøkkelansatte og i forbindelse med styrekompensasjon

11.2 Board authorisation for share capital increases in connection with the Company's share options for Executive Management and in connection with Board compensation.

I samsvar med styrets forslag ble følgende vedtatt:

In accordance with the Board of Director's proposal, the following resolution was made:

"Selskapets styre tildeles fullmakt til å gjennomføre kapitalforhøyelse, på følgende vilkår:


"The Board is authorised to increase the Company's share capital, on the following conditions:

- | | | | |
|----|--|----|---|
| a) | <i>Aksjekapitalen skal, i en eller flere omganger, kunne forhøyes med inntil NOK 5.998,43 tilsvarende 5 % av aksjekapitalen.</i> | a) | <i>The share capital may, in one or more rounds, be increased by a total amount of up to NOK 5,998.43 corresponding to 5% of the share capital.</i> |
| b) | <i>Aksjonærenes fortrinnsrett etter aksjeloven § 10-4 kan fravikes av styret.</i> | b) | <i>The preferential rights pursuant to Section 10-4 of the Private Limited Liability Companies Act may be set aside by the Board of Directors.</i> |
| c) | <i>Fullmakten gjelder fra registrering i Foretaksregisteret og frem til og med dato for ordinær generalforsamling i 2023, dog ikke senere enn 30. juni 2023.</i> | c) | <i>The authorisation shall be effective from the date it is registered in the Norwegian Register of Business Enterprises and shall be valid until and including the date of the Annual General Meeting in 2023, however no later than 30 June 2023.</i> |
| d) | <i>Fullmakten skal ikke omfatte kapitalforhøyelse mot innskudd i andre eiendeler enn penger, eller rett til å pådra Selskapet særlige plikter.</i> | d) | <i>The authorisation does not cover share capital increases against or the right to assume special obligations on behalf of the Company.</i> |
| e) | <i>Fullmakten omfatter ikke kapitalforhøyelse i forbindelse med fusjon."</i> | e) | <i>The authorisation does not cover share capital increases in connection with mergers."</i> |

Beslutningen ble truffet med nødvendig flertall, jf. avstemmingsresultat inntatt som Vedlegg 2 til protokollen.

The resolution was passed with the required majority, cf. the result of the voting set out in Appendix 2 to the minutes.

DocuSigned by:
Masha Strømme

 Signer Name: Masha Strømme
Signing Reason: I approve this document
Signing Time: 08-Jun-22 | 02:32 PDT

00B0F4C5FC124678AC1EA9613324BE3C

Masha Strømme
(møteleder / Chair of the meeting)

DocuSigned by:
Svein Kvåle

 Signer Name: Svein Kvåle
Signing Reason: I approve this document
Signing Time: 08-Jun-22 | 02:33 PDT

04818B7E24A646A88E56EB30D45C1646

Svein Kvåle
(medundertegner / co-signer)

Vedlegg/ Appendices:

1. Fortegnelse over møtende aksjeeiere, inkludert antall aksjer og stemmer representert/ Record of attending shareholders, including the number of shares and votes represented
2. Stemmeresultater/ Voting results

Firma-/Etternavn	Fornavn	Beholdning	Repr. som
KVÅLE AS		3 021 770	Stemmeinstrukser
PAACS INVEST AS		2 689 009	Stemmeinstrukser
CANICA AS		2 021 000	Stemmeinstrukser
IQBAL	JAKOB	66 250	Stemmeinstrukser
HEFTE	ARVID	110	Fullmakt

Total Represented


ISIN:	<u>N00010852213 EXACT THERAPEUTICS AS</u>
General meeting date:	08/06/2022 10.30
Today:	08.06.2022

Number of persons with voting rights represented/attended : 1

	Number of shares	% sc
Total shares	29,992,167	
- own shares of the company	0	
Total shares with voting rights	29,992,167	
Sum own shares	0	0.00 %
Represented by proxy	110	0.00 %
Represented by voting instruction	7,798,029	26.00 %
Sum proxy shares	7,798,139	26.00 %
Total represented with voting rights	7,798,139	26.00 %
Total represented by share capital	7,798,139	26.00 %

Registrar for the company:

DNB Bank ASA



DNB Bank ASA

Registrars Department

Signature company:

EXACT THERAPEUTICS AS

DocuSigned by:



Signer Name: Masha Stromme

Signing Reason: I approve this document

Signing Time: 08-Jun-22 | 02:32 PDT

00B0F4C5FC124678AC1EA9613324BE3C

Protocol for general meeting EXACT THERAPEUTICS AS

ISIN: NO0010852213 EXACT THERAPEUTICS AS
 General meeting date: 08/06/2022 10.30
 Today: 08.06.2022

Shares class	FOR	Against	Poll in	Abstain	Poll not registered	Represented shares with voting rights
Agenda item 1 Opening of the general meeting, approval of the summons and agenda						
Ordinær	7,798,139	0	7,798,139	0	0	7,798,139
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	26.00 %	0.00 %	26.00 %	0.00 %	0.00 %	
Total	7,798,139	0	7,798,139	0	0	7,798,139
Agenda item 2 Election of chair and person to co-sign the minutes						
Ordinær	7,798,139	0	7,798,139	0	0	7,798,139
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	26.00 %	0.00 %	26.00 %	0.00 %	0.00 %	
Total	7,798,139	0	7,798,139	0	0	7,798,139
Agenda item 3 Approval of the financial statements and the board of directors' report						
Ordinær	7,798,139	0	7,798,139	0	0	7,798,139
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	26.00 %	0.00 %	26.00 %	0.00 %	0.00 %	
Total	7,798,139	0	7,798,139	0	0	7,798,139
Agenda item 4 Approval of the auditor's remuneration						
Ordinær	7,798,139	0	7,798,139	0	0	7,798,139
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	26.00 %	0.00 %	26.00 %	0.00 %	0.00 %	
Total	7,798,139	0	7,798,139	0	0	7,798,139
Agenda item 5 Election of board members						
Ordinær	7,798,139	0	7,798,139	0	0	7,798,139
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	26.00 %	0.00 %	26.00 %	0.00 %	0.00 %	
Total	7,798,139	0	7,798,139	0	0	7,798,139
Agenda item 6 Election of nomination committee						
Ordinær	7,798,139	0	7,798,139	0	0	7,798,139
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	26.00 %	0.00 %	26.00 %	0.00 %	0.00 %	
Total	7,798,139	0	7,798,139	0	0	7,798,139
Agenda item 7 Remuneration to the members of the board of directors						
Ordinær	7,798,139	0	7,798,139	0	0	7,798,139
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	26.00 %	0.00 %	26.00 %	0.00 %	0.00 %	
Total	7,798,139	0	7,798,139	0	0	7,798,139
Agenda item 8 Remuneration to the members of the nomination committee						
Ordinær	7,798,139	0	7,798,139	0	0	7,798,139
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	26.00 %	0.00 %	26.00 %	0.00 %	0.00 %	
Total	7,798,139	0	7,798,139	0	0	7,798,139
Agenda item 9 Remuneration to the members of remuneration committee						
Ordinær	7,798,139	0	7,798,139	0	0	7,798,139
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	26.00 %	0.00 %	26.00 %	0.00 %	0.00 %	
Total	7,798,139	0	7,798,139	0	0	7,798,139
Agenda item 10 Remuneration to the members of the audit committee						
Ordinær	7,798,139	0	7,798,139	0	0	7,798,139

Shares class	FOR	Against	Poll in	Abstain	Poll not registered	Represented shares with voting rights
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	26.00 %	0.00 %	26.00 %	0.00 %	0.00 %	
Total	7,798,139	0	7,798,139	0	0	7,798,139
Agenda item 11.1 Board authorisation for share capital increases in connection with acquisitions, etc.						
Ordinær	7,798,139	0	7,798,139	0	0	7,798,139
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	26.00 %	0.00 %	26.00 %	0.00 %	0.00 %	
Total	7,798,139	0	7,798,139	0	0	7,798,139
Agenda item 11.2 Board authorisation for share capital increases in connection with the Company's share options for Executive Management and in connection wi						
Ordinær	7,798,139	0	7,798,139	0	0	7,798,139
votes cast in %	100.00 %	0.00 %		0.00 %		
representation of sc in %	100.00 %	0.00 %	100.00 %	0.00 %	0.00 %	
total sc in %	26.00 %	0.00 %	26.00 %	0.00 %	0.00 %	
Total	7,798,139	0	7,798,139	0	0	7,798,139

Registrar for the company:

DNB Bank ASA


DNB Bank ASA

Registrars Department

Share information

Signature company:

EXACT THERAPEUTICS AS

DocuSigned by:



Signer Name: Masha Stromme
 Signing Reason: I approve this document
 Signing Time: 08-Jun-22 | 02:32 PDT

Name	Total number of shares	Nominal value	Share capital	Voting rights
Ordinær	29,992,167	0.00	119,968.67	Yes
Sum:				

§ 5-17 Generally majority requirement
 requires majority of the given votes

§ 5-18 Amendment to resolution
 Requires two-thirds majority of the given votes
 like the issued share capital represented/attended on the general meeting

Certificate Of Completion

Envelope Id: 2AF2AEF364E942179C300CEA786D1BA3	Status: Completed
Subject: Please DocuSign: AGM 2022 Minutes EXACT Therapeutics AS.pdf, Shareholder Representation AGM 202...	
Source Envelope:	
Document Pages: 12	Signatures: 4
Certificate Pages: 5	Initials: 0
AutoNav: Enabled	Envelope Originator:
Enveloped Stamping: Disabled	Dominic Moreland
Time Zone: (UTC+01:00) Brussels, Copenhagen, Madrid, Paris	Ullernchausseen 64
	Oslo, Oslo 0379
	dominic@exact-tx.com
	IP Address: 81.159.255.222

Record Tracking

Status: Original	Holder: Dominic Moreland	Location: DocuSign
6/8/2022 11:25:28 AM	dominic@exact-tx.com	

Signer Events

Signer Events	Signature	Timestamp
Masha Stromme masha_stromme@fastmail.fm chair of board Exact-Tx EXACT-Tx Security Level: Email, Account Authentication (Required)	<i>Masha Stromme</i> Signature Adoption: Pre-selected Style Signed by link sent to masha_stromme@fastmail.fm Signature ID: 00B0F4C5-FC12-4678-AC1E-A9613324BE3C Using IP Address: 193.214.231.158 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document I approve this document I approve this document	Sent: 6/8/2022 11:30:27 AM Viewed: 6/8/2022 11:31:47 AM Signed: 6/8/2022 11:32:31 AM

Electronic Record and Signature Disclosure:
Accepted: 6/8/2022 11:31:47 AM
ID: 9f4b2ab1-e047-4211-aebc-08322ab96998

Svein Kvåle Svein@exact-tx.com Chief Operating Officer EXACT Therapeutics AS Security Level: Email, Account Authentication (Required)	<i>Svein Kvåle</i> Signature Adoption: Pre-selected Style Signed by link sent to Svein@exact-tx.com Signature ID: 04818B7E-24A6-46A8-8E56-EB30D45C1646 Using IP Address: 193.214.231.158 With Signing Authentication via DocuSign password With Signing Reasons (on each tab): I approve this document	Sent: 6/8/2022 11:30:28 AM Viewed: 6/8/2022 11:33:29 AM Signed: 6/8/2022 11:36:46 AM
---	--	--

Electronic Record and Signature Disclosure:
Not Offered via DocuSign

In Person Signer Events

Signature

Timestamp

Editor Delivery Events

Status

Timestamp

Agent Delivery Events

Status

Timestamp

Intermediary Delivery Events	Status	Timestamp
-------------------------------------	---------------	------------------

Certified Delivery Events	Status	Timestamp
----------------------------------	---------------	------------------

Carbon Copy Events	Status	Timestamp
---------------------------	---------------	------------------

Witness Events	Signature	Timestamp
-----------------------	------------------	------------------

Notary Events	Signature	Timestamp
----------------------	------------------	------------------

Envelope Summary Events	Status	Timestamps
--------------------------------	---------------	-------------------

Envelope Sent	Hashed/Encrypted	6/8/2022 11:30:28 AM
Certified Delivered	Security Checked	6/8/2022 11:33:29 AM
Signing Complete	Security Checked	6/8/2022 11:36:46 AM
Completed	Security Checked	6/8/2022 11:36:46 AM

Payment Events	Status	Timestamps
-----------------------	---------------	-------------------

Electronic Record and Signature Disclosure

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Exact Therapeutics AS (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Exact Therapeutics AS:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: anders@exact-tx.com

To advise Exact Therapeutics AS of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at spiros@exact-tx.com and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Exact Therapeutics AS

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to anders@exact-tx.com and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Exact Therapeutics AS

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to anders@exact-tx.com and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Exact Therapeutics AS as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Exact Therapeutics AS during the course of your relationship with Exact Therapeutics AS.